Stoke Therapeutics Showcases Zorevunersen for Dravet Syndrome at AES 2024

Stoke Therapeutics Advances Epilepsy Treatment Research at AES 2024

Stoke Therapeutics, Inc., a pioneering biotechnology company specializing in RNA medicine, is set to showcase its latest research at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place from December 6-10 in Los Angeles, California. The firm will present compelling data on zorevunersen, a groundbreaking candidate for the first disease-modifying treatment specifically targeting Dravet syndrome, a severe and often debilitating form of epilepsy. As Dravet syndrome impacts patients from infancy and is characterized by frequent and severe seizures, the potential of zorevunersen presents a significant advancement in therapeutic options for this vulnerable population.

Dr. Barry Ticho, Chief Medical Officer at Stoke Therapeutics, emphasizes the promising results observed in patients who were already on optimal anti-seizure medications prior to their treatment with zorevunersen. The data stems from a Phase 1/2 study involving nine patients, who received an initial dose of 70mg, followed by a 45mg dose in an open-label extension. The outcomes indicate not only a sustained reduction in seizure frequency but also noteworthy improvements in cognitive and behavioral functioning, as assessed by the Vineland-3 tool over a 24-month period. The tolerability of zorevunersen further strengthens its profile as a potentially transformative treatment for Dravet syndrome.

During the AES meeting, Stoke Therapeutics will also host a virtual symposium on December 9 at 8:30 AM Eastern, bringing together notable clinicians and patient advocates to discuss the implications of zorevunersen in the management of Dravet syndrome. Presentations will delve into how zorevunersen may not only address the immediate challenges of seizure control but also modify disease progression and enhance overall patient outcomes. With sessions scheduled for December 8 and 9, the event underscores Stoke's dedication to advancing innovative therapies that aim to improve the lives of patients and families affected by this challenging condition.

In addition to the primary focus on zorevunersen, the presentations will feature esteemed professionals from leading academic institutions, reinforcing the treatment’s relevance in pediatric epilepsy care. Stoke Therapeutics’ commitment to research and development is evident in its approach to addressing unmet medical needs in the field of epilepsy, particularly for complex conditions like Dravet syndrome. This strategic involvement in the AES meeting underscores the company's role in shaping the future of epilepsy treatment and highlights its ongoing efforts to foster collaboration within the medical community.